Three cases of refractory bullous pemphigoid in the elderly treated successfully with ultra-low-dose rituximab

Article Dermatology

Low-Dose Rituximab for Bullous Pemphigoid. Protocol and Single-Center Experience

C. Suarez-Carantona et al.

Summary: Low-dose rituximab is an effective and safe therapeutic option for bullous pemphigoid, achieving acceptable remission rates and steroid-sparing activity.

ACTAS DERMO-SIFILIOGRAFICAS (2023)

添加到收藏夹

Letter Dermatology

Clinical response to rituximab and improvement in quality of life in patients with bullous pemphigoid and mucous membrane pemphigoid

H. Rashid et al.

BRITISH JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Letter Dermatology

Ultralow-dose rituximab in pemphigus: a single-centre experience

K. Simpson et al.

BRITISH JOURNAL OF DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris

Napatra Tovanabutra et al.

Summary: This study provides detailed temporal and serologic outcomes of rituximab treatment for pemphigus vulgaris, which can guide clinical trial planning and manage expectations for clinicians and patients.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

添加到收藏夹

Letter Dermatology

Mortality and clinical response of patients with bullous pemphigoid treated with rituximab

D. S. Yoo et al.

BRITISH JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis

Yu Dong et al.

Summary: Rituximab showed efficacy and safety in treating adult patients with ITP. A low-dose regimen may be an effective alternative to the standard dose, achieving similar response rates at 12 months but with lower risks and costs.

BIOMED RESEARCH INTERNATIONAL (2021)

添加到收藏夹

Article Dermatology